These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36311474)

  • 1. Efficacy and safety of polyherbal formulation as an add-on to standard-of-care in mild-to-moderate COVID-19: A randomized, double-blind, placebo-controlled trial.
    Patankar SB; Gorde A; Joshi K; Suryawanshi K; Soni P; Shah T; Patankar S; Jha D; Raje R; Rangnekar H
    J Ayurveda Integr Med; 2022; 13(4):100653. PubMed ID: 36311474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of two siddha polyherbal decoctions, Nilavembu Kudineer and Kaba Sura Kudineer, along with standard allopathy treatment in the management of mild to moderate symptomatic COVID-19 patients-a double-blind, placebo-controlled, clinical trial.
    Srivastava A; Rengaraju M; Srivastava S; Narayanan V; Gupta V; Upadhayay R; Kumar J; Parameswaran S; KanakavalliKadarkarai ; AarthiVelmurugan
    Trials; 2021 Aug; 22(1):570. PubMed ID: 34454572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of herbal extracts to restore respiratory health and improve innate immunity in COVID-19 positive patients with mild to moderate severity: A structured summary of a study protocol for a randomised controlled trial.
    Rangnekar H; Patankar S; Suryawanshi K; Soni P
    Trials; 2020 Nov; 21(1):943. PubMed ID: 33225970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.
    Vergis N; Phillips R; Cornelius V; Katsarou A; Youngstein T; Cook L; Willicombe M; Pilay C; Shturova T; Almonte M; Charania A; Turner R; Kon OM; Cooke G; Thursz M; Cherlin S; Wason J; Milojkovic D; Innes AJ; Cooper N
    Trials; 2021 Apr; 22(1):270. PubMed ID: 33845867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind study on the efficacy of oral domperidone versus placebo for reducing SARS-CoV-2 viral load in mild-to-moderate COVID-19 patients in primary health care.
    Rabanal Basalo A; Navarro Pablos M; Viejo Pinero N; Vila Méndez ML; Molina Barcena V; Montilla Bernabé A; Villanueva Morán MDP; Blanco Gallego AM; Guirao Sánchez C; Juárez Antón S; Fernández Rodríguez Á; Revuelta Puigdollers ML; Sarriá Sánchez MT; Martín Alegre C; Martínez Álvarez MÁ; Mestre de Juan M; Mielgo Salvador R; Gijón Seco MT; Saníger Herrera JM; Rodríguez Jiménez ME; Navas de la Peña B; Santa Cruz Hernández J; Abad Esteban AM; Díaz Martín R; García Pérez L; Herrero Vanrell P; Arias de Saavedra Criado MI; Vaquero Vinent A; López Gómez V; Montegrifo Rentero VM; Simón Miguel L; Campo Martos I; Ortiz Zamorano S; Izquierdo Zamarriego MJ; Vázquez Carrión I; López Valero RM; Gil C; Martínez A; Soler López B
    Ann Med; 2023; 55(2):2268535. PubMed ID: 37847999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised controlled trial to compare efficacy of standard care alone and in combination with homoeopathic treatment of moderate/severe COVID-19 cases.
    Kaur H; Bawaskar R; Khobragade A; Kalra D; Packiam V; Khan MY; Kaur T; Sharma M; Verma NK; Kaushik S; Khurana A
    PLoS One; 2023; 18(11):e0292783. PubMed ID: 37967089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of Link Natural Sudarshana, an Ayurvedic herbal preparation in COVID-19 patients: A phase II multicenter double-blind randomized placebo-controlled trial.
    Wijewickrama A; Idampitiya D; Karunarathne M; Pahalagamage S; Sellahewa K; Govindapala D; Kalambarachchi H; Sooriyarachchi R; Chandrarathne N; Goonaratna C; Perera J
    J Ethnopharmacol; 2024 Apr; 323():117535. PubMed ID: 38070837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial.
    Wilkinson T; Dixon R; Page C; Carroll M; Griffiths G; Ho LP; De Soyza A; Felton T; Lewis KE; Phekoo K; Chalmers JD; Gordon A; McGarvey L; Doherty J; Read RC; Shankar-Hari M; Martinez-Alier N; O'Kelly M; Duncan G; Walles R; Sykes J; Summers C; Singh D;
    Trials; 2020 Jul; 21(1):691. PubMed ID: 32736596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the Unani Regimen as an Add-On to Standard Treatment in Hospitalised RT-PCR-Confirmed Mild to Moderate COVID-19 Patients: An Open-Label Randomized Controlled Trial.
    Kishore J; Kumar R; Nazli T; Ahmad A; Kumar P; Khan AA
    Cureus; 2023 May; 15(5):e38574. PubMed ID: 37284399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, Randomized, Open-Label, Blinded End Point, Two-Arm, Comparative Clinical Study to Evaluate the Efficacy and Safety of a Fixed Ayurvedic Regimen (FAR) as Add-on to Conventional Treatment in the Management of Mild and Moderate COVID-19 Patients.
    Gupta A; Vedula S; Srivastava R; Tamoli S; Mundhe N; Wagh DN; Batra S; Patil M; Pawar HB; Rai RK
    J Pharm Bioallied Sci; 2021; 13(2):256-267. PubMed ID: 34349488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Double-blind Multicenter Two-arm Randomized Placebo-controlled Phase-III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin α1 as an Add-on Treatment to Existing Standard of Care Treatment in Moderate-to-severe COVID-19 Patients.
    Shetty A; Chandrakant NS; Darnule RA; Manjunath BG; Sathe P
    Indian J Crit Care Med; 2022 Aug; 26(8):913-919. PubMed ID: 36042753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial.
    Manomaipiboon A; Pholtawornkulchai K; Poopipatpab S; Suraamornkul S; Maneerit J; Ruksakul W; Phumisantiphong U; Trakarnvanich T
    Trials; 2022 Aug; 23(1):714. PubMed ID: 36028897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial.
    Griffiths G; Fitzgerald R; Jaki T; Corkhill A; Marwood E; Reynolds H; Stanton L; Ewings S; Condie S; Wrixon E; Norton A; Radford M; Yeats S; Robertson J; Darby-Dowman R; Walker L; Khoo S;
    Trials; 2020 Jun; 21(1):544. PubMed ID: 32560744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of intravenous vitamin C in management of moderate and severe COVID-19: A double blind randomized placebo controlled trial.
    Kumar V; Bhushan D; Supriya S; Ganapule AA; Lohani P; Shyama ; Pandey S; Majhi PK; Anand U; Kumar R; Bhadani UK
    J Family Med Prim Care; 2022 Aug; 11(8):4758-4765. PubMed ID: 36352995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.